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Background
Drug reaction with eosinophilia and systemic symptoms
(DRESS) is a rare but severe cutaneous drug adverse reac-
tion (SCAR) with a not well known pathogenesis. Strong
genetic associations between HLA groups and drug allergy
have been reported but seem to be specific for a type of
SCAR, one drug and an ethnic group. Using a pangenomic
approach, effective even on a small effective, by an inno-
vating method, the Comparative Genomic Hybridization
(CGH) technique the objective of this study was to deter-
mine whether some copy number variations (CNV) were
associated with the occurrence of DRESS while studying
only well-defined DRESS patients.
Patients and Methods
In 18 patients with a DRESS score ≥5 according to
Kardaun’s criteria for Regsicar, CGH array was performed
on 1M Agilent arrays. Each patient was hybridized with a
sex-matching control. Five different controls (3 females
and 2 males) were used. For the analysis of the CNV, we
defined as significant every variation (i) that included three
consecutives mer, (ii) with different limits (intersection
CNV), (iii) shared by 2 patients and (iv) shared by 2 differ-
ent controls. Each variation was verified in the online and
in the local databases (>3000 subjects).
Results
Among 674 identified and 23 selected CNV, 2 were shared
by 4 patients. These 2 CNV were rare in the databases and
contained OMIM genes, KLRC2 and CESP1. Five other
patients had CNV at the CES1 locus and 2 other patients
at the KLRC2 locus. CNV at the CES1 locus were either
deletion of the gene or amplification of the pseudogene.
Every CNV at the KLRC2 locus were amplifications.
Discussion
The CESP1 gene is the pseudogene of the gene encoding
carboxylesterase 1 that is one of the major enzyme for
drug metabolism. Both genes are contigus. The pseudo-
gene could be inhibitor of the gene. The KLRC2 gene
encodes a lectin type receptor from the NK receptor
family that activates the cytotoxic answer. It is associated
with high granulysin expression, which is implicated in
SCAR. A genetically disturbed drug metabolism could
induce drug intolerance. This phenomenon associated
with an amplified cytotoxic answer (after herpes virus
reactivation?) could explain most symptoms seen during
DRESS.
Conclusion
This study is, to our knowledge, the first one to use CGH
array to identify candidate gene in SCAR, could identified
2 interesting genes. These data have to be confirmed by
replication studies and functional assays.
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